Position in EXEL
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$5,441
+$1,152 QoQ
Shares Held
100
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#685
of 754 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JNBA Financial Advisors holds $3,807,089 across 13 Biotechnology names. EXEL ranks #5 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CELC |
Celcuity Inc.
|
35,753 | $3,740,478 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
500 | $27,470 | |
| 3 | TLSA |
Tiziana Life Sciences Ltd
|
12,000 | $15,360 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
140 | $8,010 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
100 | $5,441 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8 | $3,973 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3 | $1,870 | |
| 8 | CYTK |
Cytokinetics Inc
|
17 | $1,448 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,441 | 100 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $4,289 | 100 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $4,383 | 100 | Shares | Sole | 2026-01-26 | |
| 2025-09-30 | $4,130 | 100 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $4,408 | 100 | Shares | Sole | 2025-07-24 | |
| No filing history on record for this holder in this stock. | ||||||